The Technical AnalystExchange: TSX Industry: Biotechnology
Microbix Biosystems Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.47% $0.335
America/New_York / 3 mai 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 45.74 mill |
| EPS: | 0.0300 |
| P/E: | 11.17 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 136.55 mill |
| Avg Daily Volume: | 0.0750 mill |
| RATING 2024-05-03 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.52x |
| Company: PE 11.17 | sector: PE 21.44 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 11.17 | industry: PE -18.01 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0940 (-128.07%) $-0.429 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.325 - 0.345 ( +/- 2.99%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.335 (-1.47% ) |
| Volume | 0.0523 mill |
| Avg. Vol. | 0.0750 mill |
| % of Avg. Vol | 69.73 % |
| Signal 1: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MBX.TO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MBX.TO
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.